Kenvue CEO lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports

Kenvue's interim CEO recently engaged Robert F. Kennedy Jr. to counter claims linking Tylenol to autism in an upcoming report, a move prompted by earlier indications of a potential U.S. health secretary announcement on the matter despite medical consensus on the drug's safety during pregnancy. This development led to an initial 9%+ decline in Kenvue shares, which have since partially recovered, further complicating the outlook for a company already under investor pressure and viewed as an acquisition target.

Analysis

Kenvue (KVUE) is facing significant headline risk following a report that its interim CEO met with Robert F. Kennedy Jr. to counter claims linking Tylenol to autism. This defensive measure was prompted by suggestions that the U.S. health secretary might announce a potential link, which contradicts guidance from the FDA and other leading medical organizations that affirm acetaminophen's safety during pregnancy. The market reacted sharply to the initial news, with KVUE shares falling over 9% to $18.62 before a marginal recovery. This issue compounds existing investor concerns, as the article notes Wall Street already views Kenvue as an acquisition target due to lackluster performance. The core of the risk lies in uncertainty; while Kenvue cites a lack of safe alternatives and medical consensus on safety, the article also states that recent studies on the matter have yielded conflicting conclusions with no single firm evidence, creating a precarious situation for the company's key over-the-counter product.

Key Decisions for Investors

• Investors should closely monitor for any official announcements from the U.S. Department of Health and Human Services or the release of the referenced report, as these will be the primary catalysts for near-term volatility.
• The Tylenol headline risk exacerbates existing concerns about the company's 'lackluster performance', so investors should assess whether the current stock price adequately discounts both this new reputational threat and the underlying fundamental weakness.
• The stock's decline could make KVUE a more attractive M&A target on valuation, but the significant litigation and reputational risk may also deter potential acquirers, creating a highly uncertain outlook for any M&A premium.
• Given the conflicting scientific conclusions mentioned, positions in KVUE carry elevated binary risk; a definitive regulatory or scientific validation of Tylenol's safety could trigger a sharp recovery, whereas a negative finding would likely lead to further downside.